The initial public offering (IPO) market showed signs of life for the first time in more than a month as Boston-based Avalyn Pharma filed a registration statement on Wednesday seeking to raise capital ...

Replimune Group Inc. shares cratered after the U.S. Food and Drug Administration delivered a second, definitive rejection of its lead skin cancer therapy, trigg ...

Debloat tools promise a faster, cleaner Windows 11 in a few clicks. In reality, they barely change performance and sometimes ...

GitHub has launched Copilot CLI into general availability, bringing generative AI directly to the terminal. Integrated with ...

Bengaluru: The U.S. ​Food and Drug Administration ​on Friday declined to approve Replimune's drug for ​advanced skin cancer ...

Replimune (REPL) stock plunges as the company seeks layoffs following the FDA rejection of its cancer drug RP1 for melanoma.

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced ...

Replimune (REPL) stock crashed 19% after FDA rejected RP1 melanoma treatment for second time, citing trial design issues.

Replimune (REPL) stock plunged 19% after FDA rejected RP1 melanoma treatment for the second time, citing trial design issues.

I’ve spent the last few months doing something I probably should’ve done sooner: testing ChatGPT, Gemini, and Claude side by ...

The FDA in a complete response letter to Replimune maintained its original objection to the single-arm trial the biotech used ...

Replimune disagrees with the FDA about whether the data set, upon which breakthrough therapy designation was awarded, is sufficient to allow this promising medicine to be made available to advanced ...